XTX Topco Ltd Invests $1.10 Million in GSK plc (NYSE:GSK)

XTX Topco Ltd bought a new stake in shares of GSK plc (NYSE:GSK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 28,604 shares of the pharmaceutical company’s stock, valued at approximately $1,101,000.

Other large investors also recently added to or reduced their stakes in the company. JTC Employer Solutions Trustee Ltd raised its position in shares of GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after buying an additional 8,800,822 shares during the last quarter. Fisher Asset Management LLC increased its holdings in GSK by 10.6% in the 4th quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company’s stock valued at $557,267,000 after acquiring an additional 1,436,488 shares during the last quarter. Primecap Management Co. CA lifted its stake in GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after purchasing an additional 1,773,020 shares in the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after purchasing an additional 1,512,442 shares during the last quarter. Finally, Equity Investment Corp grew its position in shares of GSK by 1.0% during the second quarter. Equity Investment Corp now owns 3,433,202 shares of the pharmaceutical company’s stock valued at $132,178,000 after purchasing an additional 34,631 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GSK shares. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group began coverage on shares of GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, Jefferies Financial Group boosted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $50.00.

GSK Stock Down 2.0 %

Shares of GSK opened at $40.80 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The business has a fifty day moving average of $41.39 and a 200 day moving average of $41.69. The company has a market cap of $84.56 billion, a PE ratio of 14.78, a P/E/G ratio of 1.41 and a beta of 0.66. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. On average, sell-side analysts expect that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.77%. GSK’s dividend payout ratio is currently 54.71%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.